W. B. London

734 total citations
17 papers, 492 citations indexed

About

W. B. London is a scholar working on Neurology, Cancer Research and Surgery. According to data from OpenAlex, W. B. London has authored 17 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Neurology, 11 papers in Cancer Research and 6 papers in Surgery. Recurrent topics in W. B. London's work include Neuroblastoma Research and Treatments (16 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Adrenal and Paraganglionic Tumors (5 papers). W. B. London is often cited by papers focused on Neuroblastoma Research and Treatments (16 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Adrenal and Paraganglionic Tumors (5 papers). W. B. London collaborates with scholars based in United States, United Kingdom and Australia. W. B. London's co-authors include Susan L. Cohn, Peter F. Ambros, G M Brodeur, A D Pearson, Gudrun Schleiermacher, J.M. Maris, Javed Khan, Michelle Haber, Akira Nakagawara and R Spitz and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

W. B. London

16 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. B. London United States 6 423 233 232 120 55 17 492
I.M. Ambros Austria 3 304 0.7× 153 0.7× 148 0.6× 62 0.5× 43 0.8× 7 331
Ruediger Spitz Germany 11 594 1.4× 335 1.4× 262 1.1× 154 1.3× 73 1.3× 12 651
Sheena C. Tenney United States 8 501 1.2× 213 0.9× 187 0.8× 165 1.4× 33 0.6× 11 568
Carlsen Nl Denmark 3 376 0.9× 167 0.7× 143 0.6× 65 0.5× 58 1.1× 5 390
Garrett M. Brodeur United States 7 346 0.8× 284 1.2× 156 0.7× 97 0.8× 26 0.5× 8 506
Hiroaki Yamaoka Japan 13 189 0.4× 298 1.3× 118 0.5× 74 0.6× 60 1.1× 24 479
Josef Mališ Czechia 9 213 0.5× 148 0.6× 93 0.4× 66 0.6× 32 0.6× 27 303
A G McGuckin United Kingdom 9 267 0.6× 198 0.8× 97 0.4× 62 0.5× 14 0.3× 11 365
Lee McDaniel United States 8 234 0.6× 244 1.0× 202 0.9× 117 1.0× 18 0.3× 12 438
S J Yeh United States 5 296 0.7× 170 0.7× 69 0.3× 119 1.0× 17 0.3× 7 383

Countries citing papers authored by W. B. London

Since Specialization
Citations

This map shows the geographic impact of W. B. London's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. B. London with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. B. London more than expected).

Fields of papers citing papers by W. B. London

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. B. London. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. B. London. The network helps show where W. B. London may publish in the future.

Co-authorship network of co-authors of W. B. London

This figure shows the co-authorship network connecting the top 25 collaborators of W. B. London. A scholar is included among the top collaborators of W. B. London based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. B. London. W. B. London is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Schleiermacher, Gudrun, Véronique Mosseri, W. B. London, et al.. (2012). Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer. 107(8). 1418–1422. 129 indexed citations
2.
Weiser, Daniel A., Mark L. Laudenslager, Eric Rappaport, et al.. (2011). Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.. Journal of Clinical Oncology. 29(15_suppl). 9514–9514. 11 indexed citations
3.
London, W. B., K. K. Matthay, Peter F. Ambros, et al.. (2010). Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database.. Journal of Clinical Oncology. 28(15_suppl). 9518–9518. 2 indexed citations
4.
Cohn, Susan L., et al.. (2010). Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology. 28(15_suppl). 9517–9517. 4 indexed citations
5.
Yanik, Greg, Marguerite T. Parisi, Arlene Naranjo, et al.. (2010). MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.. Journal of Clinical Oncology. 28(15_suppl). 9516–9516. 4 indexed citations
6.
Ambros, Peter F., I.M. Ambros, G M Brodeur, et al.. (2009). International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer. 100(9). 1471–1482. 252 indexed citations
7.
8.
London, W. B., John M. Maris, Hideaki Shimada, et al.. (2008). Prognostic markers for stage 3 neuroblastoma (NB): A report from the International Neuroblastoma Risk Group (INRG) project. Journal of Clinical Oncology. 26(15_suppl). 10009–10009. 3 indexed citations
9.
Shusterman, Suzanne, W. B. London, S. D. Gillies, et al.. (2008). Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study. Journal of Clinical Oncology. 26(15_suppl). 3002–3002. 11 indexed citations
10.
Cohn, Susan L., et al.. (2007). Update on the development of the international neuroblastoma risk group (INRG) classification schema. Journal of Clinical Oncology. 25(18_suppl). 9503–9503. 4 indexed citations
11.
Attiyeh, Edward F., Yaël P. Mossé, Sharon J. Diskin, et al.. (2007). Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study. Journal of Clinical Oncology. 25(18_suppl). 9500–9500. 1 indexed citations
12.
Attiyeh, Edward F., Yaël P. Mossé, Cynthia Winter, et al.. (2005). Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children’s Oncology Group study. Journal of Clinical Oncology. 23(16_suppl). 6–6. 14 indexed citations
13.
London, W. B., R P Castleberry, Katherine K. Matthay, et al.. (2005). Evidence for an age cut-off greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group (COG). Journal of Clinical Oncology. 23(16_suppl). 8500–8500. 2 indexed citations
14.
Constine, L.S., Rebecca Marcus, Allen R. Chauvenet, et al.. (2005). Patterns of Failure After Response-Based, Dose-Dense Therapy for Intermediate/High Risk Pediatric Hodgkin’s Disease (POG 9425). International Journal of Radiation Oncology*Biology*Physics. 63. S21–S22. 3 indexed citations
15.
Villablanca, Judith G., R C Seeger, Hiro Shimada, et al.. (2005). Outcome of high risk (HR) stage 3 neuroblastoma (NB) with myeloablative therapy and 13-cis-retinoic Acid. Journal of Clinical Oncology. 23(16_suppl). 8503–8503. 3 indexed citations
16.
17.
Omura‐Minamisawa, Motoko, Mitchell B. Diccianni, Ray Chang, et al.. (2001). p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.. PubMed. 7(11). 3481–90. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by I.M. Ambros Breakdown of academic impact, for papers by Ruediger Spitz Breakdown of academic impact, for papers by Sheena C. Tenney Breakdown of academic impact, for papers by Carlsen Nl Breakdown of academic impact, for papers by Garrett M. Brodeur Breakdown of academic impact, for papers by Hiroaki Yamaoka Breakdown of academic impact, for papers by Josef Mališ Breakdown of academic impact, for papers by A G McGuckin Breakdown of academic impact, for papers by Lee McDaniel Breakdown of academic impact, for papers by S J Yeh
Rankless by CCL
2026